| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Sesamolin targets the MAPK signaling cascade by preventing the phosphorylation of JNK, p38 MAPKs, and caspase-3, but not ERK-MAPK.
|
|---|---|
| ln Vitro |
In vitro, Sesamolin inhibits lipid peroxidation in rat liver and kidney, demonstrating strong antioxidative activity. It protects microglia and PC12 cells against H2O2-induced cell injury by suppressing ROS generation and inhibiting p38 MAPK and caspase-3 activation. It functions as a potent free radical scavenger.
|
| ln Vivo |
In vivo, Sesamolin exhibits neuroprotective effects, as demonstrated in animal models of oxidative stress and neurodegeneration. Its lipid-lowering effects make it relevant for cardiovascular research. It has also been shown to enhance the stability of oils, preventing rancidity.
|
| Enzyme Assay |
In vitro enzyme assays for Sesamolin typically involve measuring its antioxidant capacity using cell-free systems such as the DPPH (2,2-diphenyl-1-picrylhydrazyl) or ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging assays. The compound is incubated with the radical solution, and the decrease in absorbance is measured spectrophotometrically. Lipid peroxidation inhibition is assessed in rat liver or kidney microsomes using the thiobarbituric acid reactive substances (TBARS) assay.
|
| Cell Assay |
In vitro cell-based assays for Sesamolin are conducted using neuronal cell lines such as PC12 or microglial cells. Cells are pre-treated with the compound and then exposed to an oxidative stressor like H2O2. Cell viability is measured using MTT or CCK-8 assays. Markers of apoptosis, such as caspase-3 activation and ROS production, are quantified using fluorescent probes or ELISA to evaluate the compound's neuroprotective and antioxidant effects.
|
| Animal Protocol |
In vivo animal studies for Sesamolin often employ rodent models of neurodegeneration or oxidative stress. For example, rats may be subjected to cerebral ischemia-reperfusion injury, and the compound is administered orally or intraperitoneally. Neuroprotection is assessed by measuring infarct volume, neurological deficit scores, and biochemical markers of oxidative stress in brain tissue.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Sesamolin from natural product sources suggest it is absorbed and can reach systemic circulation. As a lipophilic compound, it is expected to have good tissue distribution, including penetration into the brain, which supports its neuroprotective effects. Detailed PK parameters (e.g., half-life, Cmax, bioavailability) are limited in publicly available sources.
|
| Toxicity/Toxicokinetics |
Sesamolin is considered to have a low toxicity profile, consistent with its origin as a dietary component from sesame. It has been used in traditional medicine and is generally recognized as safe. No significant acute or chronic toxicity has been reported in the available literature, though comprehensive toxicological studies are limited.
|
| References | |
| Additional Infomation |
Sesamolin belongs to the benzodiazepine class of compounds. It has been reported to be found in flax leaf iberian grass, coleus, and other organisms with relevant data. See also: Sesame oil (partial).
Sesamolin is a natural product belonging to the lignan class. It is studied for its potential in preventing and treating diseases associated with oxidative stress and inflammation, including cardiovascular and neurodegenerative disorders. Its antioxidant activity is linked to its ability to form stable free radical intermediates. It is not an approved drug but is widely used as a research tool. |
| Molecular Formula |
C20H18O7
|
|---|---|
| Molecular Weight |
370.3527
|
| Exact Mass |
370.105
|
| Elemental Analysis |
C, 64.86; H, 4.90; O, 30.24
|
| CAS # |
526-07-8
|
| Related CAS # |
526-07-8
|
| PubChem CID |
101746
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
520.8±50.0 °C at 760 mmHg
|
| Melting Point |
93 - 94ºC (Decomposes)
|
| Flash Point |
219.2±30.0 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
2.88
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
544
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1C([H])([H])[C@]2([H])[C@@]([H])(OC3C([H])=C([H])C4=C(C=3[H])OC([H])([H])O4)OC([H])([H])[C@]2([H])[C@@]1([H])C1C([H])=C([H])C2=C(C=1[H])OC([H])([H])O2
|
| InChi Key |
ZZMNWJVJUKMZJY-AFHBHXEDSA-N
|
| InChi Code |
InChI=1S/C20H18O7/c1-3-15-17(25-9-23-15)5-11(1)19-13-7-22-20(14(13)8-21-19)27-12-2-4-16-18(6-12)26-10-24-16/h1-6,13-14,19-20H,7-10H2/t13-,14-,19+,20+/m0/s1
|
| Chemical Name |
5-[[(3S,3aR,6R,6aR)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]oxy]-1,3-benzodioxole
|
| Synonyms |
Sesamolin; AI3 20978; AI320978; AI3-20978
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~270.0 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.75 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7001 mL | 13.5007 mL | 27.0015 mL | |
| 5 mM | 0.5400 mL | 2.7001 mL | 5.4003 mL | |
| 10 mM | 0.2700 mL | 1.3501 mL | 2.7001 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
